SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Introduction The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combin...

Full description

Bibliographic Details
Main Authors: Jackeline Agorreta, Ana Remirez, Ruben Pio, Luis M Montuenga, Teresa Lozano, Esther Redin, Irati Garmendia, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Juan Lasarte, Alfonso Calvo
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e001496.full

Internet

https://jitc.bmj.com/content/9/3/e001496.full

Similar Items